Search: WFRF:(Steg Philippe Gabriel)
> (2015-2019) >
A critical reapprai...
A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease
-
- Welsh, Robert C. (author)
- Mazankowski Alberta Heart Inst, Edmonton, AB, Canada.;Univ Alberta, Edmonton, AB, Canada.
-
- Roe, Matthew T. (author)
- Duke Med, Duke Clin Res Inst, Div Cardiol, Durham, NC USA.
-
- Steg, Philippe Gabriel (author)
- Univ Paris Diderot, Sorbonne Paris Cite, FACT, DHU FIRE,AP HP, Paris, France.;INSERM, U1148, Paris, France.;Imperial Coll, NHLI, Royal Brompton Hosp, London, England.
-
show more...
-
- James, Stefan (author)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
-
- Povsic, Thomas J. (author)
- Duke Med, Duke Clin Res Inst, Div Cardiol, Durham, NC USA.
-
- Bode, Christoph (author)
- Univ Freiburg, Freiburg, Germany.
-
- Gibson, Charles Michael (author)
- Harvard Med Sch, Beth Israel Deaconess Med Ctr, Cardiovasc Div, Dept Med, Boston, MA USA.
-
- Ohman, Erik Magnus (author)
- Duke Med, Duke Clin Res Inst, Div Cardiol, Durham, NC USA.
-
show less...
-
Mazankowski Alberta Heart Inst, Edmonton, AB, Canada;Univ Alberta, Edmonton, AB, Canada. Duke Med, Duke Clin Res Inst, Div Cardiol, Durham, NC USA. (creator_code:org_t)
- Elsevier BV, 2016
- 2016
- English.
-
In: American Heart Journal. - : Elsevier BV. - 0002-8703 .- 1097-6744. ; 181, s. 92-100
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Aspirin was established more than a quarter century ago as an evidence-based therapy to reduce recurrent cardiovascular events in patients with coronary artery disease based on limited data by contemporary standards. Indeed it is unclear how regulatory agencies would define the optimal dose or duration of aspirin therapy if assessed in the current era. Subsequent clinical investigation has focused on the addition of antithrombotic agents on top of baseline aspirin therapy in the acute and chronic setting to reduce patient's risk of further ischemic events, at the cost of increased bleeding complications. The current armamentarium of potent and predictable antiplatelet and antithrombotic agents has ushered in a new era where clinicians and scientists are contemplating withdrawal of previously established agents to minimize bleeding risk while sustaining efficacy; indeed, subtraction may lead to the next advance in the treatment of acute and chronic ischemic vascular disease.
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database